“…For patients with private health insurance, the review found mixed results as to whether FT was more or less protected. In Australia, men with prostate cancer experienced FT and higher out-of-pocket expenses when they were privately insured versus public hospital patients [31], which appears to be a product of the unregulated market in which specialists practice price discrimination [36]. However, the opposite was true in the US and other South East Asian countries, where patients without health insurance were more likely to report FT compared to those with health insurance [13,6,37,4,22] but were not always protected from FT.…”